Arizona TPOXX Request Process for Tribal Entities

Clinician diagnosis and identifies eligible patients with confirmed mpox.

Fill out IHS requesting form 413 and required EA-IND forms:

- Tecovirimat (TPOXX) Requesting Form 413 (IHS413)
- FDA Form 1572 - Only one per facility for all TPOXX prescribed. Return to CDC within 7 calendar days of starting treatment.
- CDC Informed Consent Form - Obtain **PRIOR** to treatment.

E-mail IHS 413 to aaron.wyatt@ihs.gov & cathy.thomas2@ihs.gov, and cc andrea.klimo@ihs.gov

IHS requests TPOXX from National Supply Service Center (NSSC) warehouse. TPOXX is **directly shipped** to IHS location or designated tribal site.

Patients treated and monitored for duration of treatment. Follow-up appointments should be on/around days 7 & 14 of treatment

Complete remaining required EA-IND forms and return to CDC via email (regaffairs@cdc.gov) or upload to ShareFile.

- CDC Patient Intake Form: Baseline assessment **PRIOR** to starting TPOXX. Submit within 7 days of treatment initiation.
- MedWatch Form: Report serious adverse events within 72 hours of awareness or sooner, if possible.
- Optional Clinical Outcome Form: Healthcare providers are strongly encouraged to complete and submit progress information to CDC during and post treatment. Return form to CDC within 7 days of last patient follow-up.

***Current as of 12/21/2022. Processes are subject to change.**